In the rapidly evolving landscape of pharmaceuticals, recombinant protein drugs have emerged as a cornerstone of modern healthcare.

In the quest for a sustainable future, the role of high-quality biological products cannot be overstated. These products, derived from living organisms or their byproducts, are revolutionizing industries and contributing significantly to environmental sustainability.

In the ever-evolving world of biopharmaceuticals, Kexing Biopharm stands as a beacon of innovation, dedicated to the R&D, production, and sales of cutting-edge recombinant protein drugs and microecological preparations.

In the realm of biopharmaceutical innovation, Kexing Biopharm stands as a beacon of cutting-edge R&D, production, and sales.

In the heart of China's biopharmaceutical landscape, Kexing Biopharm stands as a pioneer and a leader, dedicated to the industrialization of genetic engineering drugs.

Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.

Recently, the "Innovation for the World, Exploring for the Future" 2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's Series of Globalization Activities (China), organized by Kexing Biopharm, was successfully concluded in Shanghai.

On July 28 2024, Kexing Biopharm announced European Commission approval of Apexelsin®, the generic drug to Bristol Myers Squibb's and Celgene's Abraxane®(Nab-paclitaxel).